KalVista PharmaceuticalsKALV
KALV
About: KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Employees: 150
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
327% more call options, than puts
Call options by funds: $5.82M | Put options by funds: $1.36M
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
33% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]
3% more funds holding
Funds holding: 119 [Q2] → 122 (+3) [Q3]
2% less capital invested
Capital invested by funds: $572M [Q2] → $561M (-$11.2M) [Q3]
3.11% less ownership
Funds ownership: 115.18% [Q2] → 112.07% (-3.11%) [Q3]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
113%
upside
Avg. target
$24
167%
upside
High target
$30
237%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Jonathan Wolleben 38% 1-year accuracy 28 / 74 met price target | 113%upside $19 | Market Outperform Initiated | 31 Jan 2025 |
TD Cowen Stacy Ku 0% 1-year accuracy 0 / 4 met price target | 237%upside $30 | Buy Initiated | 7 Jan 2025 |
B of A Securities Tazeen Ahmad 34% 1-year accuracy 10 / 29 met price target | 147%upside $22 | Buy Initiated | 18 Dec 2024 |
HC Wainwright & Co. Andrew Fein 37% 1-year accuracy 127 / 343 met price target | 124%upside $20 | Buy Reiterated | 6 Dec 2024 |
Needham Serge Belanger 47% 1-year accuracy 60 / 129 met price target | 214%upside $28 | Buy Reiterated | 5 Dec 2024 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also submitted a New Drug Application (NDA) for sebetralstat to the Agency. If approved, sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents a.
Neutral
Business Wire
3 weeks ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista's board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 61,000 shares of KalVista common stock on January 2, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock.
Positive
Seeking Alpha
1 month ago
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025
NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the FDA, it would be the first and only on-demand oral treatment for HAE patients ages 12 and older. The global Hereditary Angioedema treatment market size is projected to reach $17.31 billion by the end of 2032.
Neutral
Business Wire
1 month ago
KalVista Appoints Jeb Ledell as Chief Operating Officer
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. “I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within.
Neutral
Business Wire
1 month ago
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for sebetralstat, a novel, investigational treatment for hereditary angioedema (HAE). “KalVista is successfully executing on the key milestones we announced a.
Neutral
Business Wire
1 month ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares of KalVista common stock on December 2, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have.
Neutral
Business Wire
2 months ago
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. “I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors,” said Ben Palleiko, Chief E.
Neutral
Business Wire
2 months ago
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT Each presentation will be live webcast on the Company's website at www.kalvista.com. After the presentations,.
Neutral
Business Wire
2 months ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 78,000 shares of KalVista common stock on November 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options hav.
Neutral
Business Wire
2 months ago
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the “Offering”). The gross proceeds to KalVista from the Offering are expected to be $55 million, before deducting underwriting discounts, commissions and other offering expenses payable by KalVista. Concurrently with the Offering, Kal.
Charts implemented using Lightweight Charts™